Opinion on Vaccines in Mexico

Select information type

Refine your search

Search tips

Published within

« | 1 | » »|

Type Product title / description Pub Price

Novavax: competitors may follow lead in regional strategy

US biotech Novavax has initiated a pivotal two-stage study for its H1N1 influenza vaccine in Mexico. Novavax's strategy of pursuing approval for the vaccine in smaller markets before targeting the US represents an alternative and faster route to market. Given the many benefits of this strategy, Datamonitor believes that it may be adopted by other small vaccine companies in the future.

Published By Datamonitor
21 Oct 2009

« | 1 | » »|

No help is available.